AI Engines For more Details: Perplexity Kagi Labs You
Allergic Rhinitis: Chlorpheniramine maleate is effective in relieving symptoms of allergic rhinitis, including sneezing, itching, runny or stuffy nose, and postnasal drip. It works by blocking the action of histamine, a substance in the body that contributes to allergic symptoms.
Hay Fever (Allergic Conjunctivitis): It can also help alleviate symptoms of hay fever, which may include itchy, watery eyes and redness. By blocking histamine receptors in the eyes, chlorpheniramine maleate reduces these symptoms.
Hives (Urticaria): Chlorpheniramine maleate is often used to relieve itching and reduce the size and number of hives in individuals experiencing allergic reactions or other causes of hives.
Pruritus (Itching): In addition to allergic conditions, chlorpheniramine maleate may be prescribed to alleviate itching associated with various dermatological conditions, such as eczema or insect bites.
Motion Sickness: Chlorpheniramine maleate has mild sedative effects and can be used to alleviate symptoms of motion sickness, such as nausea and vomiting.
Insomnia: While chlorpheniramine maleate is primarily used for its antihistamine properties, its sedative effects may also make it useful in treating insomnia, particularly in cases where itching or allergies contribute to sleep disturbances.
Side Effects: Common side effects of chlorpheniramine maleate may include drowsiness, dizziness, dry mouth, blurred vision, constipation, and urinary retention. These side effects are usually mild and transient but can be more pronounced in some individuals.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.2 | 0.3 | 13 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3 | 2.7 | 0.11 |
| Allergies | 5.8 | 2.9 | 1 |
| Allergy to milk products | 1.8 | 1.6 | 0.13 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 5.4 | 4.5 | 0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.8 | 1 | 1.8 |
| Ankylosing spondylitis | 4.3 | 0.8 | 4.37 |
| Anorexia Nervosa | 1.3 | 2 | -0.54 |
| Antiphospholipid syndrome (APS) | 0.8 | 0.3 | 1.67 |
| Asthma | 4.9 | 3.4 | 0.44 |
| Atherosclerosis | 1.5 | 1.4 | 0.07 |
| Atrial fibrillation | 2.6 | 2.1 | 0.24 |
| Autism | 8.1 | 8.3 | -0.02 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.9 | 2.1 | -1.33 |
| Carcinoma | 4.1 | 2.3 | 0.78 |
| Celiac Disease | 1.8 | 3.7 | -1.06 |
| Cerebral Palsy | 1.9 | 1 | 0.9 |
| Chronic Fatigue Syndrome | 4.1 | 4.5 | -0.1 |
| Chronic Kidney Disease | 3.9 | 2 | 0.95 |
| Chronic Lyme | 0.4 | 0.8 | -1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.4 | 0 |
| Chronic Urticaria (Hives) | 1.7 | 0.7 | 1.43 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 1 | 0.7 |
| Cognitive Function | 2.4 | 1.6 | 0.5 |
| Colorectal Cancer | 5.8 | 2.6 | 1.23 |
| Constipation | 1.1 | 0.7 | 0.57 |
| Coronary artery disease | 2 | 1.7 | 0.18 |
| COVID-19 | 9 | 8.1 | 0.11 |
| Crohn's Disease | 7.2 | 4.4 | 0.64 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 1 | 1.9 | -0.9 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 1.5 | 1.1 | 0.36 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 9.8 | 7.3 | 0.34 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.9 | 1.5 | 0.27 |
| Endometriosis | 3 | 1.5 | 1 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.2 | 2.4 | 0.33 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3 | 1.1 | 1.73 |
| Functional constipation / chronic idiopathic constipation | 4 | 2.5 | 0.6 |
| gallstone disease (gsd) | 2.8 | 1.6 | 0.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.5 | 0.8 |
| Generalized anxiety disorder | 3 | 2.2 | 0.36 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.7 | 0.7 | 1.43 |
| Graves' disease | 1.6 | 2.7 | -0.69 |
| Gulf War Syndrome | 0.6 | 1.6 | -1.67 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 3.1 | 1.6 | 0.94 |
| Heart Failure | 2.9 | 1.6 | 0.81 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.3 | 0.3 | 3.33 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.6 | 0.5 |
| hyperglycemia | 2.3 | 2.2 | 0.05 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.3 | 4.1 | 0.05 |
| Hypothyroidism | 0.5 | 0.7 | -0.4 |
| Hypoxia | 3.4 | 0.3 | 10.33 |
| IgA nephropathy (IgAN) | 1.6 | 3 | -0.88 |
| Inflammatory Bowel Disease | 6.8 | 7.7 | -0.13 |
| Insomnia | 1.7 | 2.9 | -0.71 |
| Intelligence | 1.1 | 0.1 | 10 |
| Intracranial aneurysms | 1.1 | 0.3 | 2.67 |
| Irritable Bowel Syndrome | 6.7 | 4.5 | 0.49 |
| ischemic stroke | 2.7 | 1.7 | 0.59 |
| Liver Cirrhosis | 6.7 | 5.1 | 0.31 |
| Long COVID | 5.8 | 6.2 | -0.07 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1.2 | 1.3 | -0.08 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.7 | 1.5 | -1.14 |
| ME/CFS without IBS | 1.6 | 2.4 | -0.5 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.9 | 1 | 0.9 |
| Metabolic Syndrome | 7.2 | 7.1 | 0.01 |
| Mood Disorders | 9.9 | 6.4 | 0.55 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 6.7 | 3.9 | 0.72 |
| Multiple system atrophy (MSA) | 1.1 | 0.4 | 1.75 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.4 | -7 |
| Neuropathy (all types) | 1.2 | 1.8 | -0.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.8 | 4.2 | 0.14 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 9.1 | 7.1 | 0.28 |
| obsessive-compulsive disorder | 3.7 | 3.3 | 0.12 |
| Osteoarthritis | 2.3 | 1.4 | 0.64 |
| Osteoporosis | 2.2 | 1.9 | 0.16 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7.3 | 4.5 | 0.62 |
| Polycystic ovary syndrome | 4.4 | 2.8 | 0.57 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.3 | -0.08 |
| Primary sclerosing cholangitis | 2.4 | 1.8 | 0.33 |
| Psoriasis | 3.2 | 2.7 | 0.19 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.6 | 3.3 | 1 |
| Rosacea | 0.5 | 0.7 | -0.4 |
| Schizophrenia | 6.2 | 2.7 | 1.3 |
| scoliosis | 0.4 | 0.3 | 0.33 |
| Sjögren syndrome | 2.7 | 2.8 | -0.04 |
| Sleep Apnea | 1.3 | 1.3 | 0 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 0.6 | 1.83 |
| Stress / posttraumatic stress disorder | 3.5 | 3 | 0.17 |
| Systemic Lupus Erythematosus | 3.6 | 1.3 | 1.77 |
| Tic Disorder | 0.8 | 1.3 | -0.63 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 3.3 | 3.4 | -0.03 |
| Type 2 Diabetes | 7.5 | 6.4 | 0.17 |
| Ulcerative colitis | 4.3 | 5 | -0.16 |
| Unhealthy Ageing | 3.7 | 2.2 | 0.68 |
| Vitiligo | 1.3 | 1.4 | -0.08 |
